UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 215

of '肝病患者的化疗肝毒性和剂量调整'

215
TI
Fulminant hepatic failure secondary to erlotinib.
AU
Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD
SO
Clin Gastroenterol Hepatol. 2007;5(8):917. Epub 2007 Jul 10.
 
Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.
AD
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. wliu3@bics.bwh.harvard.edu
PMID